LC
ALNY icon

Lindbrook Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Lindbrook Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$161K Buy
596
+50
+9% +$12.8K 0.01% 484
2024
Q4 		$128K Sell
546
-24
-4% -$6.31K 0.01% 486
2024
Q3 		$157K Buy
570
+57
+11% +$14.8K 0.01% 443
2024
Q2 		$125K Buy
513
+277
+117% +$43.7K 0.01% 469
2024
Q1 		$35.3K Sell
236
-133
-36% -$22.2K ﹤0.01% 927
2023
Q4 		$70.6K Buy
369
+100
+37% +$17K 0.01% 635
2023
Q3 		$47.6K Buy
269
+22
+9% +$4.2K 0.01% 712
2023
Q2 		$46.9K Buy
247
+45
+22% +$8.92K 0.01% 741
2023
Q1 		$40.5K Sell
202
-54
-21% -$11.4K ﹤0.01% 772
2022
Q4 		$60.8K Buy
256
+41
+19% +$8.74K 0.01% 621
2022
Q3 		$43K Buy
215
+46
+27% +$8.77K 0.01% 698
2022
Q2 		$25K Buy
169
+3
+2% +$426 ﹤0.01% 885
2022
Q1 		$27K Sell
166
-17
-9% -$2.59K ﹤0.01% 880
2021
Q4 		$31K Sell
183
-3
-2% -$558 ﹤0.01% 876
2021
Q3 		$35K Buy
186
+13
+8% +$2.44K 0.01% 544
2021
Q2 		$29K Sell
173
-8
-4% -$1.17K 0.01% 643
2021
Q1 		$26K Buy
181
+15
+9% +$2.26K 0.01% 650
2020
Q4 		$22K Buy
166
+5
+3% +$668 0.01% 641
2020
Q3 		$23K Buy
161
+102
+173% +$14.5K 0.01% 561
2020
Q2 		$9K Buy
59
+7
+13% +$944 ﹤0.01% 854
2020
Q1 		$6K Buy
+52
New +$6K ﹤0.01% 905

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lindbrook Capital's ALNY Position: Q1 2025 in Review

Lindbrook Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 9.2% in Q1 2025, buying an estimated $12.8K and bringing the position to 596 shares worth $161K. The position accounts for 0.01% of the portfolio, ranked #484.

Lindbrook Capital first reported a position in ALNY in Q1 2020 and has held it in 21 quarters since. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Lindbrook Capital held 596 shares of Alnylam Pharmaceuticals worth $161K as of Q1 2025.
  • Lindbrook Capital bought 50 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $12.8K.
  • Alnylam Pharmaceuticals made up 0.01% of Lindbrook Capital's portfolio in Q1 2025, its #484 holding.
  • Lindbrook Capital first reported a position in Alnylam Pharmaceuticals in Q1 2020 and has held it in 21 quarters since.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.